SAN

79.01

+0.89%↑

SHL.DE

41.6

+0.7%↑

ORNBV.FI

69.65

+1.24%↑

QDEL

24.04

+4.34%↑

ACB

3.55

-1.11%↓

SAN

79.01

+0.89%↑

SHL.DE

41.6

+0.7%↑

ORNBV.FI

69.65

+1.24%↑

QDEL

24.04

+4.34%↑

ACB

3.55

-1.11%↓

SAN

79.01

+0.89%↑

SHL.DE

41.6

+0.7%↑

ORNBV.FI

69.65

+1.24%↑

QDEL

24.04

+4.34%↑

ACB

3.55

-1.11%↓

SAN

79.01

+0.89%↑

SHL.DE

41.6

+0.7%↑

ORNBV.FI

69.65

+1.24%↑

QDEL

24.04

+4.34%↑

ACB

3.55

-1.11%↓

SAN

79.01

+0.89%↑

SHL.DE

41.6

+0.7%↑

ORNBV.FI

69.65

+1.24%↑

QDEL

24.04

+4.34%↑

ACB

3.55

-1.11%↓

Search

Almirall SA

Închisă

SectorSănătate

13.76 0.58

Rezumat

Modificarea prețului

24h

Curent

Minim

13.58

Maxim

13.82

Indicatori cheie

By Trading Economics

Venit

13M

21M

Vânzări

-14M

260M

P/E

Medie Sector

60.7

110.024

EPS

0.1

Marjă de profit

8.059

Angajați

2,026

EBITDA

12M

66M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+4.48% upside

Dividende

By Dow Jones

Următoarele câștiguri

23 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-80M

2.6B

Deschiderea anterioară

13.18

Închiderea anterioară

13.76

Sentimentul știrilor

By Acuity

55%

45%

296 / 351 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Almirall SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 feb. 2026, 22:31 UTC

Câștiguri

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18 feb. 2026, 22:18 UTC

Câștiguri

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18 feb. 2026, 22:11 UTC

Câștiguri

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18 feb. 2026, 21:52 UTC

Câștiguri

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18 feb. 2026, 23:56 UTC

Market Talk

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18 feb. 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 feb. 2026, 23:46 UTC

Market Talk

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18 feb. 2026, 23:34 UTC

Market Talk
Câștiguri

Brambles' Cost Control Stands Out to Bull -- Market Talk

18 feb. 2026, 23:33 UTC

Market Talk

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18 feb. 2026, 23:32 UTC

Market Talk

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18 feb. 2026, 22:45 UTC

Câștiguri

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18 feb. 2026, 22:44 UTC

Market Talk

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18 feb. 2026, 22:37 UTC

Câștiguri

Nutrien 4Q EPS $1.18 >NTR.T

18 feb. 2026, 22:37 UTC

Câștiguri

Nutrien 4Q Sales $5.34B >NTR.T

18 feb. 2026, 22:35 UTC

Câștiguri

Pan American Silver 4Q EPS $1.07 >PAAS

18 feb. 2026, 22:35 UTC

Câștiguri

Pan American Silver 4Q Rev $1.18B >PAAS

18 feb. 2026, 22:30 UTC

Câștiguri

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18 feb. 2026, 22:29 UTC

Câștiguri

Kinross Gold 4Q EPS 75c >K.T

18 feb. 2026, 22:22 UTC

Câștiguri

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18 feb. 2026, 22:22 UTC

Market Talk

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18 feb. 2026, 22:16 UTC

Câștiguri

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18 feb. 2026, 22:05 UTC

Câștiguri

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18 feb. 2026, 22:03 UTC

Câștiguri

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18 feb. 2026, 22:02 UTC

Câștiguri

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18 feb. 2026, 22:02 UTC

Câștiguri

Kaiser Aluminum 4Q Sales $929M >KALU

18 feb. 2026, 22:02 UTC

Câștiguri

Kaiser Aluminum 4Q EPS $1.68 >KALU

18 feb. 2026, 22:00 UTC

Câștiguri

Kinross Gold 4Q Adj EPS 67c >KGC

18 feb. 2026, 22:00 UTC

Câștiguri

Kinross Gold 4Q Sales $2.02B >KGC

18 feb. 2026, 21:56 UTC

Câștiguri

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18 feb. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Comparație

Modificare preț

Almirall SA Așteptări

Obiectiv de preț

By TipRanks

4.48% sus

Prognoză pe 12 luni

Medie 14 EUR  4.48%

Maxim 14 EUR

Minim 14 EUR

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAlmirall SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

1 ratings

0

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

9.76 / 10.2Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Strong Bullish Evidence

Sentiment

By Acuity

296 / 351 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Almirall SA

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
help-icon Live chat